Dr. Manuj Agarwal, co-founder of the Prostate Cancer Institute of America (PCIA), recently hosted a compelling episode of the American Brachytherapy Society podcast, spotlighting the evolution of prostate brachytherapy—a minimally invasive, highly effective treatment for localized prostate cancer.
Shining a Light on the History and Future of LDR Brachytherapy
This in-depth discussion revisited the historical rise of low-dose-rate (LDR) brachytherapy, examined the shifts in its utilization over the past two decades, and explored how seed implant techniques have been refined through technological and clinical innovations.
With LDR brachytherapy once at the forefront of prostate cancer treatment, Dr. Agarwal led a thoughtful conversation about the challenges the field has faced—including declining utilization—and what it will take to restore its rightful place as a first-line treatment option for appropriately selected patients.
Key Takeaways
The episode emphasizes the importance of:
- Physician-industry collaboration to support access and affordability
- Workflow enhancements to improve procedural efficiency
- Continued education to guide patient selection and optimize outcomes
Whether you’re a doctor, patient or healthcare industry leader, this conversation provides essential context and a forward-looking perspective on how brachytherapy can remain a vital part of the prostate cancer treatment landscape.
🎧 Listen to the Full Episode
👉 At Prostate Cancer Institute of America (PCIA), we specialize in LDR prostate brachytherapy, offering cutting-edge, patient-centered care. Learn more about our services
